+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease



Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease



Journal of Neural Transmission Parkinson's Disease and Dementia Section 5(3): 193-202



A double-blind, cross-over trial with 12 patients with Alzheimer's disease (AD) was carried out primarily to test the suitability of this design in the investigation of the clinical effects of selegiline (10 mg/day) in AD. Cerebrospinal fluid (CSF) samples for the determination of concentrations of noradrenaline (NA) and several monoamine metabolites were collected at baseline and at the end of both four-week treatment periods (placebo and selegiline). The severity of dementia was assessed using Ferm's and Gottfries-Bråne-Steen (GBS) dementia scales. The concentrations of the dopamine metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC) and the NA metabolites, 3,4-dihydroxyphenylglycol (DHPG), and 3-methoxy-4-hydroxyphenyl glycol (MHPG) decreased significantly during selegiline treatment. There was a clear trend of reduction in concentrations of homovanillic acid (HVA) during selegiline treatment, whereas the concentrations of NA, 5-hydroxyindoleacetic acid (5-HIAA), and tryptophan did not differ significantly. The study design was not suitable for the analysis of the clinical results as there was a significant carry-over effect in both scales. As only the first period data could be used in the analysis, there were no significant differences in the scores of Ferm's or GBS scales, but clear positive trends could be detected in favour of selegiline.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008574417

Download citation: RISBibTeXText

PMID: 8369100

DOI: 10.1007/bf02257674


Related references

Various effects of monoamine oxidase inhibitors under conditions of complete monoamine oxidase inhibition on the serotonin, dopamine and noradrenaline levels in the rat brain. Acta Biologica et Medica Germanica 17(4): 488-497, 1966

A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease. European Journal of Medicinal Chemistry 62: 745-753, 2013

Long-term treatment with a monoamine oxidase-B inhibitor selegiline of ageing rats Effects on amino acid and monoamine neurotransmitters. Society for Neuroscience Abstracts 20(1-2): 1709, 1994

Inhibition of monoamine oxidase B and the neuroprotective effects of selegiline. Lieberman, A, Olanow, C W, Youdim, M B H, Tipton, K Neurological Disease and Therapy; Monoamine oxidase inhibitors in neurological diseases 201-216, 1994

Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease. Bioorganic and Medicinal Chemistry 23(13): 3722-3729, 2016

Effects of selegiline on catecholamine and indoleamine content relate to monoamine oxidase-A inhibition in rat brain. Society for Neuroscience Abstracts 23(1-2): 2037, 1997

Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide. Clinical Neuropharmacology 16(4): 332-337, 1993

Effects of monoamine oxidase inhibition on female sexual behavior, serotonin levels and type A and B monoamine oxidase activity. Neuroendocrinology 34(4): 245-251, 1982

Deuterium isotope effects in relation to the chemical mechanism of monoamine oxidase. In: New reflections on monoamine oxidase inhibition, 1963. Ann New York Acad Sci 107(3): 822-839, 1963

Effects of monoamine oxidase A inhibition on plasma biogenic amine metabolites in depressed patients. Psychiatry Research. 52(3): 259-264, 1994

Varying effects of monoamine oxidase inhibitors under conditions of complete monoamine oxidase inhibition on serotonin,. Acta Biol Med Ger 17(4): 458-497, 1966

Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells. Journal of Neural Transmission 120(3): 435-444, 2013

Effects of chronic treatment with selegiline on age-related cognitive decline and longevity of Syrian hamsters The relationship to monoamine oxidase B inhibition. Pharmacopsychiatry 28(5): 183, 1995

Inhibition of platelet monoamine oxidase type B by selegiline. Journal of Clinical Pharmacology 37(7): 597-601, 1997

Pharmacokinetics of oral moclobemide in healthy human subjects and effects on monoamine oxidase activity in platelets and excretion of urine monoamine metabolites. European Journal of Clinical Pharmacology 28(1): 89-96, 1985